GleamWall
中文EN

RYTM RHYTHM PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1649904 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY61.0%
TTM net income YoY-0.8%
TTM EPS YoY6.1%
Revenue 3-yr CAGR65.5%
Net income 3-yr CAGR—

Margins

Gross margin88.2%
Operating margin-66.7%
Net margin-69.0%
FCF margin—
EBITDA margin—

Returns

ROE-163.7%
ROA-40.8%
ROIC (approx.)-83.0%
Asset turnover0.59x

Leverage & solvency

Liabilities / assets54.5%
Debt / equity1.17x
Current ratio2.78x
Interest coverage-10.27x

Cash quality & payout

Operating cash flow / net income0.42x
Accruals ratio-23.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$92.13M$71.25M$60.11M$57.25M$51.30M$48.50M$32.70M$41.83M
Cost of revenue$12.17M$8.93M$7.16M$4.80M$5.50M$5.54M$3.65M$3.79M
Gross profit$79.96M$62.32M$52.95M$52.45M$45.80M$42.96M$29.06M$38.04M
R&D expense$52.48M$43.43M$41.73M$42.03M$46.03M$42.31M$36.97M$41.17M
SG&A expense$66.75M$67.45M$63.59M$57.48M$52.42M$45.95M$39.09M$38.13M
Operating income-$39.27M-$48.55M-$52.36M-$47.06M-$52.65M-$45.30M-$47.00M-$41.26M
Interest expense$4.50M$4.54M$4.58M$4.62M$4.74M$5.82M$5.41M$5.45M
Pretax income-$40.76M-$48.85M-$55.09M-$47.54M-$52.79M-$46.30M-$49.42M-$43.38M
Income tax$610,000$444,000$545,000-$31,000$111,000$337,000$80,000-$90,000
Net income-$41.37M-$49.30M-$55.64M-$47.51M-$52.90M-$46.63M-$49.50M-$43.29M
EPS (basic)-0.61-0.73-0.83—-0.82-0.75-0.81—
EPS (diluted)-0.61-0.73-0.83—-0.82-0.75-0.81—
Weighted avg. shares (diluted)69.05M68.59M67.97M—66.26M63.68M63.06M—
Balance sheet
Cash & equivalents$39.98M$65.61M$62.14M$54.30M$52.08M$135.59M$106.09M$89.14M
Short-term investments$280.96M$265.28M$278.49M$334.65M$363.97M$155.44M$208.39M$231.43M
Receivables$39.12M$40.41M$34.19M$26.08M$33.03M$26.12M$17.82M$18.51M
Inventory$31.19M$30.52M$28.65M$25.75M$22.11M$18.87M$19.32M$18.74M
Current assets$419.36M$426.56M$430.09M$466.92M$494.80M$360.68M$369.29M$374.20M
PP&E, net$569,000$103,000$1.06M$1.10M$237,000$297,000$462,000$632,000
Intangibles$16.68M$4.89M$5.11M$5.32M$5.53M$5.75M$5.96M$6.17M
Total assets$443.13M$437.27M$442.32M$480.20M$506.87M$372.73M$386.69M$392.27M
Current liabilities$150.89M$123.59M$103.20M$105.94M$104.27M$129.46M$111.82M$115.52M
Short-term debt$14.75M$12.70M$10.13M$7.30M$5.56M$3.78M$1.59M$1.54M
Long-term debt$87.92M$93.40M$98.34M$100.89M$103.41M$106.01M$107.93M$108.27M
Total debt$102.67M$106.10M$108.47M$108.18M$108.97M$109.79M$109.52M$109.81M
Total liabilities$241.59M$219.97M$204.70M$210.17M$211.19M$239.15M$223.60M$227.72M
Shareholders' equity$87.97M$102.98M$122.91M$139.07M$148.82M-$11.91M$18.95M$21.73M
Net debt$62.69M$40.49M$46.33M$53.88M$56.89M-$25.79M$3.43M$20.67M
Shares outstanding69.31M68.82M68.45M67.21M66.68M63.91M63.49M62.39M
Cash flow statement
Operating cash flow-$3.06M-$9.15M-$44.19M-$25.39M-$26.62M-$23.31M-$40.35M-$18.84M
Capital expenditure———$953,000————
Free cash flow———-$26.34M————
Investing cash flow-$16.11M$14.01M$57.05M$30.35M-$246.35M$54.03M$24.81M$21.16M
Financing cash flow-$6.25M-$1.17M-$5.40M-$2.95M$189.30M-$889,000$32.50M$38.33M
Stock-based compensation$25.02M$26.06M$23.10M$19.27M$18.81M$15.88M$12.86M$10.56M

Free plan shows the latest 8 periods; Pro shows all 43 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.